Adaptimmune Therapeutics
Latest round
- Series A
Last raised
- Sep 2014
Total raised
- $104M
Investors
- 12
About Adaptimmune Therapeutics
Founded in 2008 in Abingdon, UK, Adaptimmune Therapeutics PLC specializes in engineered T-cell therapies aimed at combating solid tumors.Adaptimmune specializes in advanced cell therapy solutions aimed at treating challenging solid tumors. The company’s core offerings center around engineered T-cell therapies, which utilize a patient's own cells to create a targeted immune response against cancer. These therapies, known as Afami-cel, Lete-cel, and Uza-cel, focus on specific cancer antigens and have the potential to transform the treatment landscape for patients with various cancer types. Adaptimmune serves a global clientele, including healthcare providers and research institutions, with a strong presence in markets such as the United States and Europe.Adaptimmune generates revenue through its proprietary cell therapy products, which are typically administered in clinical settings by healthcare professionals. The company engages in partnerships and collaborations with various healthcare institutions and pharmaceutical companies, facilitating the distribution and administration of its therapies.Adaptimmune plans to further develop its pipeline of engineered T-cell therapies, aiming to launch new products targeting additional cancer types in the coming years.
Who invested in Adaptimmune Therapeutics
12 investors across 1 round
See all investors in Adaptimmune Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Sep 25, 2014
Amount
$104M
Investors
Questions about Adaptimmune Therapeutics
Who invested in Adaptimmune Therapeutics?
Adaptimmune Therapeutics has 12 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Adaptimmune Therapeutics raised?
Adaptimmune Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Adaptimmune Therapeutics last raise money?
Adaptimmune Therapeutics's most recent round on record is a Series A, in Sep 2014.
What does Adaptimmune Therapeutics do?
Founded in 2008 in Abingdon, UK, Adaptimmune Therapeutics PLC specializes in engineered T-cell therapies aimed at combating solid tumors.
Where is Adaptimmune Therapeutics headquartered?
Adaptimmune Therapeutics is headquartered in Abingdon, UK.
Which VCs invest in companies like Adaptimmune Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Adaptimmune Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Adaptimmune Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.